LENIOLISIB PHOSPHATE - Generic Drug Details

What are the generic drug sources for leniolisib phosphate and what is the scope of freedom to operate?

Leniolisib phosphate is the generic ingredient in one branded drug marketed by Pharming and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Leniolisib phosphate has forty-six patent family members in forty countries.

One supplier is listed for this compound.

Summary for LENIOLISIB PHOSPHATE

International Patents:	46
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	8
DailyMed Link:	LENIOLISIB PHOSPHATE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LENIOLISIB PHOSPHATE

Constraining patent/regulatory exclusivity:

TREATMENT OF ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA (PI3K DELTA) SYNDROME (APDS) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for LENIOLISIB PHOSPHATE

Drug Class	Kinase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Cytochrome P450 1A2 Inhibitors Organic Anion Transporting Polypeptide 1B1 Inhibitors Organic Anion Transporting Polypeptide 1B3 Inhibitors Phosphoinositide 3-Kinase delta Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for LENIOLISIB PHOSPHATE

L03AX	Other immunostimulants
L03A	IMMUNOSTIMULANTS
L03	IMMUNOSTIMULANTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for LENIOLISIB PHOSPHATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharming	JOENJA	leniolisib phosphate	TABLET;ORAL	217759-001	Mar 24, 2023		RX	Yes	Yes	8,653,092		Y	Y
Pharming	JOENJA	leniolisib phosphate	TABLET;ORAL	217759-001	Mar 24, 2023		RX	Yes	Yes
Pharming	JOENJA	leniolisib phosphate	TABLET;ORAL	217759-001	Mar 24, 2023		RX	Yes	Yes

International Patents for LENIOLISIB PHOSPHATE

Country	Patent Number	Title	Estimated Expiration
Slovenia	2590974
Ecuador	SP13012420
Taiwan	I534145
Denmark	2590974

LENIOLISIB PHOSPHATE Market Analysis and Financial Projection

Last updated: February 17, 2026

What Are the Market Dynamics for Leniolisib Phosphate?

Leniolisib phosphate targets the phosphoinositide 3-kinase delta (PI3Kδ) enzyme. It has received regulatory approval for treating activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency. The drug's market largely revolves around orphan disease treatment, limiting its immediate commercial scale but positioning it as a candidate for niche therapy markets.

Key Market Factors

• Indication Scope: Approved specifically for APDS, with investigational potential in other immunological disorders. The rare nature constrains large population sales, but high per-unit pricing drives revenue.

• Regulatory Approvals: The FDA approved leniolisib for APDS in 2021, with similar authorizations expected in Europe and other markets. A stable regulatory environment supports commercialization.

• Pricing and Reimbursement: As an orphan drug, leniolisib commands premium pricing. Cost estimates range from $150,000 to $200,000 annually per patient, subject to payer negotiations and regional policies.

• Market Penetration: Limited, due to the rarity of APDS (estimated prevalence: 1 in 1 million). Few healthcare providers and centers are equipped to prescribe the drug, curbing early adoption.

• Competitive Landscape: No directly comparable drugs exist. PI3K inhibitors for related indications, such as idelalisib and copanlisib, serve broader cancer markets but differ mechanistically. Future pipeline drugs may influence market share.

• Supply Chain and Manufacturing: Leniolisib is manufactured through complex synthetic processes requiring high purity standards. Manufacturing capacity constraints could impact supply if demand accelerates.

Market Trends

• Growth Drivers: Increased diagnosis of APDS, advances in genetic testing, and expanding awareness among clinicians.

• Barriers: Limited patient pool, high treatment costs, and the need for specialized healthcare facilities.

• Future Potential: Explorations into other immune disorders and autoimmune diseases could expand the market. Clinical trials in related indications are underway.

What Is the Financial Trajectory for Leniolisib Phosphate?

Revenue projections remain conservative, primarily due to the limited patient population.

Revenue Projections

Year	Estimated Global Sales	Assumptions
2023	$10-20 million	Initial market entry, early adopters, single-digit hundreds of patients treated
2024	$25-50 million	Increased awareness, expanded clinical adoption, early sign of pipeline growth
2025	$50-100 million	Broader uptake, potential for off-label use in related conditions, pipeline progress

Cost Structure

Leniolisib's costs include R&D, manufacturing, regulatory compliance, and sales & marketing. As an orphan drug, manufacturing costs are high due to stringent quality standards, but volume-based economies of scale are limited.

Profitability Outlook

Profitability hinges on market penetration and pricing negotiations given the limited patient base. Break-even is anticipated beyond 2024, assuming steady uptake and reimbursement approvals.

Investment and Funding

Partnerships with biotech firms or licensing agreements with large pharma entities may influence capital flow. Grants from rare disease programs can offset R&D costs.

Comparative Analysis with Similar Drugs

Drug	Indication	Price Range (Annual)	Market Size	Regulatory Status
Idelalisib	B-cell malignancies	$130,000-$150,000	Large, targeted cancer	Approved globally
Copanlisib	Non-Hodgkin lymphoma	$110,000-$140,000	Substantially larger	Approved in the US and Europe
Zandelisib	Lymphoma (investigational)	Under review	Expected to be smaller	Phase 2 trials ongoing
Leniolisib	APDS	$150,000-$200,000	Very small	Approved in US, EMA submissions in progress

Leniolisib's pricing aligns with other orphan disease therapies but faces a smaller market due to disease rarity.

Key Takeaways

• Leniolisib phosphate is a high-priced, niche therapy approved for APDS, with sales projections remaining modest due to a limited patient pool.
• Growth depends on improved diagnosis, expanded indications, and regulatory approvals in other regions.
• The supply chain complexity and high manufacturing costs may influence pricing and availability.
• Competitive landscape is limited, but pipeline drugs and expanding indications could reshape market dynamics.
• Investment prospects are tied to clinical trial outcomes, pipeline development, and market adoption rates.

FAQs

1. What are the primary challenges facing leniolisib's commercial success?
Limited patient populations and high treatment costs constrain sales growth. Additionally, the need for specialized healthcare infrastructure limits rapid adoption.

2. How does leniolisib compare to other PI3K inhibitors?
It is more selective for the PI3Kδ enzyme, targeting immune disorders rather than cancers. Its orphan status limits its market size compared to broader-spectrum PI3K inhibitors used in oncology.

3. Are there any ongoing trials to expand leniolisib’s use?
Yes. Clinical trials are exploring its efficacy in other immunological and autoimmune conditions, which could diversify its applications.

4. What factors could accelerate leniolisib's market growth?
Better disease awareness, expanded diagnostic capabilities, and approval for additional indications could increase patient treatment numbers.

5. How do regulatory policies impact the drug’s future?
Expedited review pathways, orphan drug designations, and favorable reimbursement policies improve market access and financial prospects.

---

References

1. FDA Approval Announcement for Leniolisib (2021).
2. Market Intelligence Reports on Rare Disease Therapies.
3. Pricing Analysis for Orphan Disease Drugs.
4. ClinicalTrials.gov for ongoing studies of Leniolisib.
5. Competitive landscape analysis of PI3K inhibitors in oncology and immunology.